|
|
|
Mercoledì 22 Agosto 2007, 13:38
|
VIVALIS RAFFORZA IL SUO PORTAFOGLIO DI PROPRIETÀ INTELLETTUALE TRAMITE UN ACCORDO DI LICENZA ESCLUSIVO CON LA NORTH CAROLINA STATE UNIVERSITY Nantes (Francia) e Raleigh (NC, USA) - 21 agosto 2007 Vivalis (NYSE-Euronext (Parigi: NL0000290641 - notizie) : VLS) ha di recente siglato un accordo di licenza di tecnologie sviluppate dalla North Carolina State University (NCSU) per la messa a punto di un metodo di produzione di cellule aviarie indifferenziate tramite l'uso di cellule germinali primordiali (PGC). Questa nuova licenza, relativa ai procedimenti e ai mezzi di coltura, si aggiunge alle 2 licenze precedentemente firmate con la NORTH CAROLINA STATE UNIVERSITY nel 2002. Grazie a questo nuovo accordo, VIVALIS conferma la sua leadership mondiale nel campo delle cellule staminali aviarie e rafforza la protezione della proprietà intellettuale della sua tecnologia di rottura EBx®. The licensed technology is covered by US patent N°6,333,192 and Europe patent N°EP1,200,556. Additional patent applications protecting this discovery are pending. The license grants VIVALIS exclusive rights to apply the methodology worldwide. The financial terms of the license remain confidential. Franck GRIMAUD, VIVALIS CEO declared : "We are very pleased to have signed this exclusive license with North Carolina State University. This agreement will strongly reinforce our intellectual property position on the industrial applications of ES cells. Vivalis now has built a world-wide unique and exhaustive avian ES cell IP portfolio, which is positioning us as the sole IP and technology provider in this field ". Vivalis partnered with NC State's Office of Technology Transfer (OTT (A074150.KQ - notizie) ) to coordinate the official licensing arrangements with the University. OTT is responsible for collaboratively fulfilling the university's mandate to benefit the greater public good through the transfer of academic research and discovery to the marketplace. ******************* Next calendar: August 30th, after Euronext closing: First half 2007 results About VIVALIS (www.vivalis.com) Vivalis (NYSE-Euronext: VLS) is a biopharmaceutical company specialised in vaccines and in viral diseases. VIVALIS' know-how and proprietary technologies are commercially exploited in three main areas: - Vaccine development and manufacturing. VIVALIS grants commercial licences to its proprietary EBx® embryonic stem cell lines to pharmaceutical and biotechnology companies active in the viral vaccine business. - Recombinant therapeutic protein and monoclonal antibody expression systems development. VIVALIS partners with pharmaceutical and biotechnology companies in this area, to which it licences its proprietary EBx® embryonic stem cell lines to manufacture recombinant therapeutic proteins. - The build-up of a proprietary portfolio of vaccines and anti-viral molecules. Based in Nantes (France), Vivalis was created in 1999 by Group GRIMAUD (1350 employees), the n°2 group worldwide in avian genetic breeding. Vivalis has established several partnerships with companies that are worldwide leaders in their respective fields, including Sanofi Pasteur, GlaxoSmithKline (Londra: GSK.L - notizie) , Novartis Vaccines, Merial and SAFC Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES cluster. About NORTH CAROLINA STATE UNIVERSITY Located in Raleigh, North Carolina, and founded in 1887 as a land-grant university, North Carolina State University today is one of the United States' top public research universities. It holds more than 570 U.S. patents and invests more than $444 million annually in research, training and extension. B Compartment of Eurolist Paris - FR0004056851 Reuters: VLS.PA - Bloomberg: VLS FP Investors Contact: VIVALIS NewCap Franck Grimaud, C.E.O. Financial communication Agency Email: investors@vivalis.com Steve Grobet / Emmanuel Huynh Tel.: +33 (0) 1 44 71 94 91 Email: vivalis@newcap.fr Copyright Hugin [CN#124054] |
|
Discuti di questa notizia sui nuovi forum di Yahoo! Finanza
Scegli azione
Altri articoli in > Economia
Yahoo! Finanza
> Comunicati Stampa |
|
|
|
Copyright © 2004 CompanynewsGroup. Tutti i diritti riservati. |
| Copyright © 2007 Yahoo! Tutti i diritti riservati. |